静脉补铁治疗左室射血分数<50%的心力衰竭伴铁缺乏患者的疗效
贾玮玲 , 李晓燕 , 赵欢 , 杨雅钗 , 杨志瑜 , 李柳
中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (6) : 534 -538.
静脉补铁治疗左室射血分数<50%的心力衰竭伴铁缺乏患者的疗效
Efficacy of intravenous iron supplementation in patients with heart failure,iron deficiency,and left ventricular ejection fraction < 50%
目的 探讨静脉补铁治疗左室射血分数 (LVEF) <50%的心力衰竭 (简称心衰) 伴铁缺乏患者的疗效。方法 将2023年1月至2024年12月间于河北医科大学第一医院心血管内科就诊的LVEF<50%的心衰伴铁缺乏患者200例随机分为常规治疗组 (100例) 和静脉补铁组 (100例)。常规治疗组给予常规抗心衰治疗,静脉补铁组在常规抗心衰治疗基础上加用羧基麦芽糖铁注射液静脉注射。观察治疗30 d后的疗效、心肺运动试验结果和药物不良反应情况。结果 静脉补铁组患者治疗后N末端B型脑钠肽前体、铁蛋白、血清铁、转铁蛋白饱和度、左心房前后径、肺动脉压均较常规治疗组显著好转,Weber心功能A级、B级占比明显增加,峰值摄氧量、无氧阈、二氧化碳当量斜率显著优于常规治疗组,且并未增加明显药物不良反应。结论 静脉补铁治疗可改善LVEF<50%的心衰伴铁缺乏患者的临床疗效和Weber心功能,且不增加药物不良反应。
Objective To investigate the efficacy of intravenous iron supplementation in patients with heart failure,iron deficiency,and left ventricular ejection fraction (LVEF) < 50%. Methods A total of 200 patients with heart failure,iron deficiency,and LVEF < 50%,who were admitted to the Department of Cardiology,The First Hospital of Hebei Medical University between January 2023 and December 2024,were randomly assigned to a conventional treatment group (100 patients) or an intravenous iron supplementation group (100 patients). The conventional treatment group received standard therapy for heart failure,and the intravenous iron supplementation group received intravenous ferric carboxymaltose,in addition to standard therapy for heart failure. After 30 days of treatment,the therapeutic efficacy,cardiopulmonary exercise test results,and adverse drug reactions were analyzed. Results Compared with the conventional treatment group,the intravenous iron supplementation group had significant improvements in N-terminal pro-B-type natriuretic peptide,ferritin,serum iron,transferrin saturation,left atrial anteroposterior diameter,and pulmonary artery pressure. Post-treatment,there were significantly more patients with Weber class A and B in the intravenous iron supplementation group,and peak oxygen uptake,anaerobic threshold,and the slope of the carbon dioxide equivalent were significantly superior to those in the conventional treatment group. Moreover,there was no significant increase in adverse drug reactions. Conclusion Intravenous iron supplementation can improve the clinical efficacy and Weber functional class in patients with heart failure,iron deficiency,and LVEF < 50%,with no increase in adverse drug reactions.
| [1] |
中华医学会心血管病学分会,中国医师协会心血管内科医师分会,中国医师协会心力衰竭专业委员会, |
| [2] |
柴松波,杜亚康,张淑娟, |
| [3] |
|
| [4] |
|
| [5] |
梁美琼,周漪琪,黄惠芬, |
| [6] |
张琳,田新瑞. 心肺运动试验对围手术期风险评估的研究进展 [J]. 心肺血管病杂志,2023,42 (4):375-379. DOI:10.3969/j.issn.1007-5062.2023.04.018. |
| [7] |
|
| [8] |
|
| [9] |
中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018 [J]. 中华心血管病杂志,2018,46 (10):760-789. DOI:10.3760/cma.j.issn.0253-3758.2018.10.004. |
| [10] |
中华医学会心血管病学分会,中国康复医学会心肺预防与康复专业委员会,中华心血管病杂志编辑委员会, |
| [11] |
|
| [12] |
|
| [13] |
戴世轩. 补充铁剂对心力衰竭伴铁缺乏患者治疗效果的Meta分析[D]. 石家庄:河北医科大学,2022. |
| [14] |
|
| [15] |
|
| [16] |
|
河北省医学科学研究课题计划(20241849)
/
| 〈 |
|
〉 |